XNK Therapeutics has actively participated in several public-private partnerships to develop its technology platform. The main collaborating partners have been Karolinska Institutet, Karolinska University Hospital, and the Royal Institute of Technology.

XNK Therapeutics is currently participating in three public-private partnerships. They have allowed the company to develop its technology within the competence center AdBIOPRO, as well as its business model within the SWElife-ATMP organization. The latest public-private partnership, the one with the competence center NextGenNK, will allow XNK Therapeutics to build further on the clinical development of its leading investigational drug candidate, CellProtect. XNK Therapeutics is always open for, and actively looking, collaboration partners.

Please contact our CEO Johan Liwing (johan.liwing@xnktherapeutics.com) for discussing research collaborative ideas.


NextGenNK is Competence Center initiated by Sweden’s innovation agency (Vinnova). It was launched in 2020 for the development of next-generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. XNK Therapeutics is a Partner within this Competence Center. Within this collaboration, one mission is to perform an open, randomized, controlled phase II trial with CellProtect in combination with a monoclonal antibody in patients with Multiple myeloma.


The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO, aims at developing competitive technology for bioproduction, focusing on the imminent paradigm shift towards continuous processes of biopharmaceuticals and on the manufacturing of emerging potent therapeutic products such as recombinant viral vector and cell products. XNK Therapeutics is a Partner within the Competence Center with the aim to establish an outscaled manufacturing protocol enabling the production of CellProtect in Sweden to support clinical studies. The work addresses biological factors governing a product of high quality.


CAMP is a Vinnova-funded project focused on the science and technology required to translate ATMPs from the lab bench to the clinic, including bioprocess development, GMP production, and logistics. CAMP drives collaboration among researchers, GMP-competent resources, industry partners, and hospitals.

The 2-year collaboration centers on the potential automatization of XNK Therapeutics’ clinical process to develop novel natural killer (NK) cell-based therapies. XNK will obtain access to Cytiva’s and Vecura’s expertise and Cytiva’s equipment to investigate how these resources can be implemented in the company’s process to expand and activate NK cells.